Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

All Issues

eGFR equations in the EHR—how lab met the request

October 2024—In patients at risk for chronic kidney disease, clinical practice guidelines released this year recommend the combined creatinine and cystatin C-based estimated glomerular filtration rate over the creatinine-based eGFR when cystatin C is available. “Cystatin C isn’t perfect itself, but a combination of the two seems to hit the sweet spot,” Angela Ferguson, PhD, D(ABCC), said in a session at the ADLM meeting in July. Dr. Ferguson is associate professor at the University of Missouri-Kansas City School of Medicine and co-director of clinical chemistry, director of immunology, and director of point-of-care testing in the Department of Pathology and Laboratory Medicine, Children’s Mercy Kansas City. The guidelines were released by the Kidney Disease: Improving Global Outcomes chronic kidney disease work group.

Can labs bridge the hematology data disconnect?

October 2024—Do clinicians understand how the technology in hematology has evolved and how laboratory data can help guide their decisions? It’s a question roundtable participants took on when they met online Aug. 29 with CAP TODAY publisher Bob McGonnagle. “There’s a disconnect with our clinical colleagues,” said Olga Pozdnyakova, MD, PhD, of the Hospital of the University of Pennsylvania. She and others spoke about solutions, instruments, AI, and reference ranges—in addition to the staffing shortage. “It is first and foremost in our minds,” Maria (Ria) Vergara-Lluri, MD, of Keck School of Medicine of USC, said of the ongoing shortage.

From the President’s Desk

October 2024—When this column comes out, many of us will be on our way to our annual meeting, held this year in Las Vegas. As I planned my presidential address for CAP24, I decided to focus on the future—the future of pathology and our future as pathologists. I’ll use this month’s column to cover the same theme. (And if some of you happen to read this column before I give my address, you will in a sense be seeing the future yourselves.)

Clinical pathology selected abstracts

October 2024—Exposure to lead is associated with irreversible adverse effects on fetal and neonatal development. Because no reliable threshold exists for determining the impact of lead exposure on children, the CDC began using the term blood lead reference values to identify children with higher blood lead levels (BLLs). Limiting exposure to lead is critical to ensuring that vulnerable populations, such as fetuses, neonates, and children, are not at risk for adverse neurodevelopmental outcomes. Lead and inorganic lead compounds are classified as carcinogens, while such metals as mercury and cadmium are considered neurotoxicants. Studies have shown a significant correlation between post-transfusion BLLs in infants and lead levels in RBC units.

Anatomic pathology selected abstracts

October 2024—Screening for colorectal cancers can involve assessing mismatch repair deficiency or microsatellite instability to identify people with Lynch syndrome, the most common hereditary syndrome causing colorectal cancer. Advanced adenomas are considered immediate precursor lesions of colorectal cancer. The authors conducted a study in which they investigated the relevance of microsatellite instability screening of advanced adenomas for Lynch syndrome in population screening. They selected advanced adenomas (n=1,572) from the Dutch colorectal cancer population screening program. All were reviewed and met one or more of the following criteria: tubulovillous (n=848, 54 percent) or villous (n=118, 7.5 percent) adenoma, diameter of 1 cm or more (n=1,286, 82 percent), or high-grade dysplasia (n=176, 11 percent).

Molecular pathology selected abstracts

October 2024—Huntington disease is a neurodegenerative disease caused by abnormal CAG trinucleotide repeats in exon one of the HTT gene, in which the number of CAG repeats affects disease presentation. Alleles with 40 or more CAG (cytosine, adenine, guanine) repeats are fully penetrant and age at disease onset is inversely correlated with number of repeats, while 36 to 39 CAG repeats are associated with reduced penetrance and fewer than 36 are not considered to cause Huntington disease. It is thought that inherited CAG repeats may undergo somatic expansion until a harmful threshold is reached before the degenerative process begins.

Pathology informatics selected abstracts

October 2024—The authors conducted a study to evaluate the Genius digital diagnostic system compared with manual light microscopy diagnosis using ThinPrep Pap test slides. Six cytologists and three cytopathologists participated in the study. They received 1.5 days of training on the Genius digital system from the manufacturer (Hologic, Marlborough, Mass.). They then analyzed 319 ThinPrep Pap test cases in the authors’ institutional cytology archive that represented a range of Bethesda System categories typically encountered in routine practice. The study participants assessed diagnostic accuracy by comparing digital and manual results to the original Pap test diagnosis, which was considered the reference diagnosis, or ground truth.

Newsbytes

October 2024—Conducting informal pathology clinics in his office to help patients better understand their diagnosis has been standard fare for John Groth, MD. But this will change in the coming months as he finishes setting up a formal clinic, replete with the technology and tools necessary to more easily educate patients at Endeavor Health’s Evanston Hospital.

Q&A column

October 2024
Q. Immunofluorescence microscopy results for antinuclear antibodies (ANAs) are reported as a titer. How can we best comply with CAP checklist requirement IMM.34120 Daily QC—Nonwaived Tests for ANA testing? Read answer.
Q. Is there a standard of care for anatomic pathology reporting? The CAP document “How to Read Your Pathology Report” states that pathologists “always perform the microscopic evaluation of a specimen, even if the final pathology report does not include a written description.” Must the testing pathology laboratory provide the patient with the microscopic description if it is requested and not included in the pathology report? Read answer.

Put It on the Board

October 2024—The two lawsuits filed by the American Clinical Laboratory Association and Association for Molecular Pathology that challenge the Food and Drug Administration’s final rule on laboratory-developed tests will be consolidated in the U.S. District Court for the Eastern District of Texas, according to a motion filed Sept. 9. During the weeks of Aug. 26 and Sept. 2, the parties to both actions conferred on how to litigate both cases “in a just, speedy, and efficient manner,” the motion says. It adds that all parties in both cases consent to the transfer of the AMP case to the Eastern District “and agree that, subject to this Court’s discretion, the two cases then should be consolidated for joint briefing and decision.”

MARKETPLACE

TRENDING